{"id":"NCT03303521","sponsor":"AstraZeneca","briefTitle":"A Study to Test Whether ZS (Sodium Zirconium Cyclosilicate) Can Reduce the Incidence of Increased Blood Potassium Levels Among Dialized Patients.","officialTitle":"A Phase 3b, Multicenter, Prospective, Randomized, Double Blind, Placebocontrolled Study to Reduce Incidence of Pre-dialysis Hyperkalemia With Sodium Zirconium Cyclosilicate (DIALIZE)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-12-14","primaryCompletion":"2018-11-07","completion":"2018-11-07","firstPosted":"2017-10-06","resultsPosted":"2020-02-20","lastUpdate":"2020-02-20"},"enrollment":196,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Hyperkalemia"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Sodium Zirconium Cyclosilicate (ZS)","otherNames":[]}],"arms":[{"label":"Sodium Zirconium Cyclosilicate (ZS)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy of ZS in the treatment of hyperkalemia in patients on hemodialysis.","primaryOutcome":{"measure":"Percentage of Responders","timeFrame":"Evaluation period runs over the last 4 weeks of the treatment period up to 8 weeks, starting after visit 11 and ending on visit 15, thus it comprises post-long inter-dialytic interval visits 12, 13, 14 and 15.","effectByArm":[{"arm":"Sodium Zirconium Cyclosilicate (SZC)","deltaMin":41.2,"sd":null},{"arm":"Placebo","deltaMin":1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":53,"countries":["United States","Japan","Russia","United Kingdom"]},"refs":{"pmids":["35135481","32588430"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D9480C00006&amp;attachmentIdentifier=c9e82fef-889a-4fa8-a7a4-d2f8c17e1653&amp;fileName=D9480C00006_CSP_redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D9480C00006&amp;attachmentIdentifier=bd3feeb6-4e7a-49da-8b34-b2ef1e35c582&amp;fileName=D9480C00006_SAP_redacted.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":96},"commonTop":["Diarrhoea","Nasopharyngitis"]}}